| RSS
Business center
Office
Post trade leads
Post
Rank promotion
Ranking
 
You are at: Home » News » International »

“Upstar” against Breast Cancer—CDK 4/6 Inhibitors: Which has the Biggest Potential among the Three?

Increase font size  Decrease font size Date:2019-08-21   Views:48

Targeted therapies have played an increasingly important role in tumor treatment in recent years. I’d like to introduce in detail an “upstart”—CDK 4/6 inhibitors in the breast cancer therapeutic area today. Pfizer’s palbociclib, Novartis’ ribociclib, and Eli Lilly’s abemaciclib have been approved for marketing and formed a situation of tripartite confrontation, wherein, the global sales of Pfizer’s palbociclib accounted for 89% of the CDK 4/6 inhibitor market in 2018 upon its first-mover advantage, however, the annual growth of palbociclib has gradually declined in recent years, and many enterprises have laid out the area. Therefore, it is still unknown as to whether which will dominate the CDK 4/6 inhibitor market in the future.

 
 
[ Search ]  [ ]  [ Email ]  [ Print ]  [ Close ]  [ Top ]

 
Total:0comment(s) [View All]  Related comment

 
Recomment
Popular
 
 
Home | About | Service | copyright | agreement | contact | about | SiteMap | Links | GuestBook | Ads service | 京ICP 68975478-1
Tel:+86-10-68645975           Fax:+86-10-68645973
E-mail:yaoshang68@163.com     QQ:1483838028